Effects of berberine on lipid profile in subjects with low cardiovascular risk

Effects of berberine on lipid profile in subjects with low cardiovascular risk
复制标题

DOI:
10.1517/14712598.2013.776037
复制
发表时间:
2013-04-01
影响因子:
4.6
通讯作者:
Maffioli, Pamela
Maffioli, Pamela
中科院分区:
医学3区
文献类型:
--
作者:
Derosa, Giuseppe;D'Angelo, Angela;Maffioli, Pamela

文献摘要

被引文献

相似文献

目的:研究设计和方法:144例白人受试者入组研究,目的:评价黄连素作为抗高胆固醇血症药物在低心血管风险患者中的疗效。经过6个月的饮食和体力活动后,患者随机服用安慰剂或黄连素500毫克,每天两次,为期3个月,在双盲,安慰剂对照设计。然后中断黄连素和安慰剂治疗2个月(洗脱期),所有患者仅继续饮食和体力活动。在洗脱期结束时,患者重新开始服用黄连素或安慰剂,每天两次,持续3个月。人体测量和代谢参数进行了评估,在运行期间,在随机化,之前和之后的washout period.Results:体重和BMI下降后,观察到的运行期间。与安慰剂相比,随机分组3个月后,黄连素降低了总胆固醇、甘油三酯和LDL胆固醇,增加了HDL胆固醇。洗脱期后,血脂恶化;之后,当小檗碱被重新引入,血脂改善再次与洗脱期相比,和安慰剂。结论:小檗碱是有效的,安全的,以轻度改善血脂在低风险的心血管疾病的受试者。
Objective: To evaluate the efficacy as antihypercholesterolemic agent of berberine in patients with low cardiovascular risk.Research design and methods: 144 Caucasian subjects were enrolled. After a 6-month run-in period following diet and practicing physical activity, patients were randomized to take placebo or berberine 500 mg twice a day, for 3 months, in a double-blind, placebo-controlled design. Berberine and placebo were then interrupted for 2 months (washout period), and all patients continued with only diet and physical activity. At the end of the washout period, patients restarted berberine or placebo twice a day for further 3 months. Anthropometric and metabolic parameters were assessed during the run-in period, at randomization, before and after the washout period.Results: A decrease of body weight and BMI was observed after the run-in period. Berberine reduced total cholesterol, triglycerides and LDL cholesterol and increased HDL cholesterol after 3 months from randomization and compared with placebo. After the washout period, lipid profile worsened; afterward, when berberine was reintroduced, lipid profile improved again both compared with the washout period, and with placebo.Conclusions: Berberine is effective and safe to mildly improve lipid profile in subjects with low risk for cardiovascular disease.